These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9551171)

  • 81. Automated analytical systems for drug development studies. Part IV. A microdialysis system to study the partitioning of lomefloxacin across an erythrocyte membrane in vitro.
    Knaub SR; Chang MF; Lunte CE; Topp EM; Riley CM
    J Pharm Biomed Anal; 1995 Dec; 14(1-2):121-9. PubMed ID: 8833974
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [Fluoroquinolones and problems of molecular mechanism of their action].
    Egorov AM; Sazykin IuO
    Antibiot Khimioter; 2000; 45(8):3-5. PubMed ID: 10989716
    [No Abstract]   [Full Text] [Related]  

  • 83. In-vitro activity of lomefloxacin against pathogenic and environmental mycobacteria.
    Banerjee DK; Ford J; Markanday S
    J Antimicrob Chemother; 1992 Aug; 30(2):236-8. PubMed ID: 1328136
    [No Abstract]   [Full Text] [Related]  

  • 84. Comparison of the pharmacodynamic properties of quinolones.
    Wiedemann B; Rustige-Wiedemann C; Kratz B
    Drugs; 1995; 49 Suppl 2():269-71. PubMed ID: 8549328
    [No Abstract]   [Full Text] [Related]  

  • 85. Recent advances in the field of quinolones.
    Takemura M; Hayakawa I
    Farmaco; 2001; 56(1-2):37-40. PubMed ID: 11347964
    [No Abstract]   [Full Text] [Related]  

  • 86. Gallbladder tissue concentrations, biliary excretion and pharmacokinetics of OPC-17116.
    Tanimura H; Uchiyama K; Kashiwagi H
    Drugs; 1995; 49 Suppl 2():341-3. PubMed ID: 8549355
    [No Abstract]   [Full Text] [Related]  

  • 87. [Current and future aspects of quinolones].
    Bush V; Dalkhoff A; Tsaĭler KhI
    Antibiot Khimioter; 1993; 38(2-3):3-8. PubMed ID: 8074561
    [No Abstract]   [Full Text] [Related]  

  • 88. [A new method of calculating tissue/blood distribution coefficient in physiological models of pharmacokinetics].
    Manuĭlov KK; Kashina LB
    Antibiot Khimioter; 1990 May; 35(5):35-6. PubMed ID: 2383153
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The measurement of a new antimicrobial quinolone in hair as an index of drug exposure.
    Uematsu T; Nakano M; Akiyama H; Nakashima M
    Br J Clin Pharmacol; 1993 Feb; 35(2):199-203. PubMed ID: 8382934
    [TBL] [Abstract][Full Text] [Related]  

  • 90. 4-quinolones and multivalent ions.
    Lewin CS; Smith JT
    J Antimicrob Chemother; 1990 Jul; 26(1):149. PubMed ID: 2271052
    [No Abstract]   [Full Text] [Related]  

  • 91. Mechanism of quinolone uptake into bacterial cells.
    Piddock LJ
    J Antimicrob Chemother; 1991 Apr; 27(4):399-403. PubMed ID: 1856120
    [No Abstract]   [Full Text] [Related]  

  • 92. Antimicrobial activity of fluoroquinolones.
    Millar B; Moore J; Hardy M; Rendall J; Koulianos G
    Vet Rec; 2021 Apr; 188(7):271-272. PubMed ID: 33835558
    [No Abstract]   [Full Text] [Related]  

  • 93. Fluoroquinolones: considerations for future use.
    Congeni BL; Thomson RB
    Pediatr Infect Dis J; 2002 Apr; 21(4):345-6. PubMed ID: 12075768
    [No Abstract]   [Full Text] [Related]  

  • 94. Microbial transformations of antimicrobial quinolones and related drugs.
    Parshikov IA; Sutherland JB
    J Ind Microbiol Biotechnol; 2012 Dec; 39(12):1731-40. PubMed ID: 23007957
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue.
    Müller M; dela Peña A; Derendorf H
    Antimicrob Agents Chemother; 2004 May; 48(5):1441-53. PubMed ID: 15105091
    [No Abstract]   [Full Text] [Related]  

  • 96. Drug interaction and pharmacological considerations during anti-infective therapy in cancer patients.
    Petitjean O; Nicolas P; Tod M
    Cancer Treat Res; 1995; 79():255-80. PubMed ID: 8746659
    [No Abstract]   [Full Text] [Related]  

  • 97. [The difluoroquinolone lomefloxacin--an broad spectrum antimicrobial drug].
    Padeĭskaia EN; Iakovlev VP
    Antibiot Khimioter; 1998; 43(2):30-9. PubMed ID: 9551171
    [No Abstract]   [Full Text] [Related]  

  • 98. Lomefloxacin, a new difluoroquinolone: in vitro activity against gram-positive and gram-negative bacteria.
    Hoban D; Grabowski M; Koss J; Weselowski V
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):77S-82S. PubMed ID: 2791502
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [In vitro evaluation of lomefloxacin].
    Dette GA; Knothe H
    Arzneimittelforschung; 1989 Aug; 39(8):832-5. PubMed ID: 2818672
    [TBL] [Abstract][Full Text] [Related]  

  • 100. In vitro assessment of the postantibiotic effect of lomefloxacin against gram-positive and gram-negative pathogens.
    Debbia EA; Pesce A; Schito GC
    Am J Med; 1992 Apr; 92(4A):45S-47S. PubMed ID: 1316070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.